Category: Publikasjoner

[nb:]Ranji P, Jonasson E, Andersson L, Filges S, Santamaría ML, Vannas C, Dolatabadi S, Gustafsson A, Myklebost O, Håkansson J, Fagman H, Landberg G, Åman P, Ståhlberg A (2024) Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development. J Transl Med 10.1186/s12967-024-05211-w

Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024). Evolutionary mode and timing of dissemination of high-grade serous carcinomas. JCI Insight. e170423. doi: 10.1172/jci.insight.170423

Zhou Y, Ray PS, Zhu J, Stein F, Rettel M, Sekaran T, Sahadevan S, Perez-Perri JI, Roth EK, Myklebost O, Meza-Zepeda LA, von Deimling A, Fu C, Brosig AN, Boye K, Nathrath M, Blattmann C, Lehner B, Hentze MW, Kulozik AE (2024) Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma Nat Commun DOI: 10.1038/s41467-024-47031-y

Anzar, I., B. Malone, P. Samarakoon, I. Vardaxis, B. Simovski, H. Fontenelle, L. A. Meza-Zepeda, R. Stratford, E. Keung, M. Burgess, H. A. Tawbi, O. Myklebost and T. Clancy (2023). «The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition.» Front. Immunol. doi: 10.3389/fimmu.2023.1226445

Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara M, Waddell N, Kondrashova O, Pearson JV, Barbour JV, Li S, Nguyen TL, Green MJ, Kaplan W, Ravishankar S, Copty J, Powell JE, Ahn JH, Kim JU, Randall RL, Tucker K, Judson I, Sarin R, Haber M, Marshall G, Cairns MJ, Blay JY, Thomas DM (2023) Heritable defects in telomere and mitotic function selectively predispose to sarcomas Science doi: 10.1126/science.abj4784

Namløs HM, Khelik K, Nakken S, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2023) Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential. Molecular Oncology doi:10.1002/1878-0261.13514 

Namløs H, Skårn M, Ahmed D, Grad I, Andresen K, Kresse S, Serra M, Scotlandi K, Llombart-Bosch A, Myklebost O, Lind G, Meza-Zepeda LA (2022) miR-486 expression is regulated by DNA methylation in osteosarcoma BMC Genomics 23:142. doi: 10.1186/s12864-022-08346-6

Misund K, Hofste op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA, Sundan A, Myklebost O, Sonneveld P, Waage A. (2022) Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence Leukemia 10.1038/s41375-022-01597-y 

Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Lønning PE, Knappskog S, Eikesdal HP (2022) Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel  monotherapy Genome Med DOI: doi: 10.1186/s13073-022-01090-2 

Georgiesh T, Namløs HM, Sharma N, Lorenz S, Myklebost O, Bjerkehagen B, Meza-Zepeda LA, Boye K (2021) Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumor. Pathology 53:713-719 doi:10.1016/j.pathol.2020.11.010

Grad I, Hanes R, Ayuda-Durán P, Kuijjer ML, Enserink JM, Meza-Zepeda LA, Myklebost O (2021) Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening. PLoS DOI:10.1371/journal.pone.0248140 

Nakken S, Saveliev V, Hofmann O, Møller P, Myklebost O, Hovig E (2020) Cancer Predisposition Sequencing Reporter (CPSR): a flexible variant report engine for high-throughput germline screening in cancer.  Int J Cancer Vol.149(11), p.1955-1960 doi: 10.1002/ijc.33749 

Peneder P, Stütz AM, Surdez D, Krumbholz M, Semper S, Chi-card M, Sheffield NC, Pierron G, Lapouble E, Tötzl M, Ergüner B, Barre-ca D, Rendeiro AF, Agaimy A, Boztug H, Engstler G, Dworzak M, Bernkopf M, Taschner-Mandl S, Ambros IM, Myklebost O, Marec-Berard P, Burchill SA, Brennan B, Strauss SJ, Whelan J, Schleiermacher G, Dirksen U, Hutter C, Boye K, Ambros PF, Delattre O, Metzler M, Bock C, Tomazou E (2021) Accurate detection and classification of Ewing sarcoma tumors based on cell-free DNA fragmentation patterns inferred from whole genome sequencing. Nature Communications 28;12(1):3230. doi: 10.1038/s41467-021-23445-w

Stabell M, Sæther T, Røhr ÅK, Gabrielsen OS, Myklebost O (2021) Methylation-dependent SUMOylation of the architectural transcription factor HMGA2. Biochemical and Biophysical Research Communications, doi: 10.1016/j.bbrc.2021.02.099 

Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, Lothe RA (2021) The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Medicine 13:142. doi: 10.1186/s13073-021-00955-2  

Bailey MH, Meyerson WU, Dursi LJ,  ….., Gerstein MB, Ding L & PCAWG Consortium [including Bjerkehagen B, Myklebost O, Zaikova O] (2020) Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples Nature Communications volume 11, Article number: 4748 DOI: 10.1038/s41467-020-18151-y  

Bhandari V, Li CH, Bristow RG, Boutros PC; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun. 11:737. doi: 10.1038/s41467-019-14052-x

Carlevaro-Fita J, Lanzós A, Feuerbach L, Hong C, Mas-Ponte D, Pedersen JS; PCAWG Drivers and Functional Interpretation Group; Johnson R; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,Myklebost O] (2020) Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol. 3:56. doi: 10.1038/s42003-019-0741-7

Cmero M, Yuan K, Ong CS, Schröder J; PCAWG Evolution and Heterogeneity Working Group; Corcoran NM, Papenfuss T, Hovens CM, Markowetz F, Macintyre G; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Inferring structural variant cancer cell fraction. Nat Commun. 11:730. doi: 10.1038/s41467-020-14351-8

Cortés-Ciriano I, Lee JJ, Xi R, Jain D, Jung YL, Yang L, Gordenin D, Klimczak LJ, Zhang CZ, Pellman DS; PCAWG Structural Variation Working Group; Park PJ; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 52:331-341. doi: 10.1038/s41588-019-0576-7

Dörnen J, Myklebost O, Dittmar (2020) Cell Fusion of Mesenchymal Stem/Stromal Cells and Breast Cancer Cells leads to the Formation of Hybrid Cells exhibiting diverse and individual (stem cell) Characteristics. International Journal of Molecular Sciences https://doi.org/10.3390/ijms21249636

Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A, Wintersinger J, Kleinheinz K, Vázquez-García I, Haase K, Jerman L, Sengupta S, Macintyre G, Malikic S, Donmez N, Livitz DG, Cmero M, Demeulemeester J, Schumacher S, Fan Y, Yao X, Lee J, Schlesner M, Boutros PC, Bowtell DD, Zhu H, Getz G, Imielinski M, Beroukhim R, Sahinalp SC, Ji Y, Peifer M, Markowetz F, Mustonen V, Yuan K, Wang W, Morris QD; PCAWG Evolution & Heterogeneity Working Group; Spellman PT, Wedge DC, Van Loo P; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) The evolutionary history of 2,658 cancers. Nature 578:122-128. doi: 10.1038/s41586-019-1907-7

Jiao W, Atwal G, Polak P, Karlic R, Cuppen E; PCAWG Tumor Subtypes and Clinical Translation Working Group; Danyi A, de Ridder J, van Herpen C, Lolkema MP, Steeghs N, Getz G, Morris QD, Stein LD; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun.11:728. doi: 10.1038/s41467-019-13825-8

Li CH, Prokopec SD, Sun R, Yousif F, Schmitz N, PCAWG Tumour Subtypes and Clinical Translation, Boutros PC, PCAWG Consortium (Including Bjerkehagen B, Myklebost O, Zaikova O) (2020) Sex differences in oncogenic mutational processes. Nature Communications 11:4330 DOI: 10.1038/s41467-020-17359-2

Li Y, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, Khurana E, Waszak S, Korbel JO, Haber JE, Imielinski M; PCAWG Structural Variation Working Group; Weischenfeldt J, Beroukhim R, Campbell PJ; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Patterns of somatic structural variation in human cancer genomes. Nature 578:112-121. doi: 10.1038/s41586-019-1913-9

Paczkowska M, Barenboim J, Sintupisut N, Fox NS, Zhu H, Abd-Rabbo D, Mee MW, Boutros PC; PCAWG Drivers and Functional Interpretation Working Group; Reimand J; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 11:735. doi: 10.1038/s41467-019-13983-9

PCAWG Transcriptome Core Group; Calabrese C, Davidson NR, Demircioğlu D, Fonseca NA, He Y, Kahles A, Lehmann KV, Liu F, Shiraishi Y, Soulette CM, Urban L, Greger L, Li S, Liu D, Perry MD, Xiang Q, Zhang F, Zhang J, Bailey P, Erkek S, Hoadley KA, Hou Y, Huska MR, Kilpinen H, Korbel JO, Marin MG, Markowski J, Nandi T, Pan-Hammarström Q, Pedamallu CS, Siebert R, Stark SG, Su H, Tan P, Waszak SM, Yung C, Zhu S, Awadalla P, Creighton CJ, Meyerson M, Ouellette BFF, Wu K, Yang H; PCAWG Transcriptome Working Group; Brazma A, Brooks AN, Göke J, Rätsch G, Schwarz RF, Stegle O, Zhang Z; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Genomic basis for RNA alterations in cancer. Nature 578:129-136. doi: 10.1038/s41586-020-1970-0

Reyna MA, Haan D, Paczkowska M, Verbeke LPC, Vazquez M, Kahraman A, Pulido-Tamayo S, Barenboim J, Wadi L, Dhingra P, Shrestha R, Getz G, Lawrence MS, Pedersen JS, Rubin MA, Wheeler DA, Brunak S, Izarzugaza JMG, Khurana E, Marchal K, von Mering C, Sahinalp SC, Valencia A; PCAWG Drivers and Functional Interpretation Working Group; Reimand J, Stuart JM, Raphael BJ; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Pathway and network analysis of more than 2500 whole cancer genomes. Nat Commun. 11:729. doi: 10.1038/s41467-020-14367-0

Rheinbay E, Nielsen MM, Abascal F, … ; PCAWG Drivers and Functional Interpretation Working Group; PCAWG Structural Variation Working Group; Weischenfeldt J, Beroukhim R, Martincorena I, Pedersen JS, Getz G; PCAWG Consortium  [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature 578:102-111. doi: 10.1038/s41586-020-1965-x

Rodriguez-Martin B, Alvarez EG, Baez-Ortega A, Zamora J, Supek F, …, PCAWG Structural Variation Working Group; Campbell PJ, Tubio JMC; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,Myklebost O] (2020) Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 52:306-319. doi: 10.1038/s41588-019-0562-0

Rubanova Y, Shi R, Harrigan CF, Li R, Wintersinger J, Sahin N, Deshwar AG; PCAWG Evolution and Heterogeneity Working Group; Morris QD; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,Myklebost O] (2020) Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun. 11:731. doi: 10.1038/s41467-020-14352-7

Serguienko A, Braadland P, Meza-Zepeda LA, Bjerkehagen B, Myklebost O (2020) Accurate 3-gene-signature for early diagnosis of liposarcoma progression. Clinical Sarcoma Research 10:4 DOI: 10.1186/s13569-020-0126-1.

Shuai S; PCAWG Drivers and Functional Interpretation Working Group; Gallinger S, Stein LD; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun. 11:734. doi: 10.1038/s41467-019-13929-1 

Sieverling L, Hong C, Koser SD, Ginsbach P, Kleinheinz K, Hutter B, Braun DM, Cortés-Ciriano I, Xi R, Kabbe R, Park PJ, Eils R, Schlesner M; PCAWG-Structural Variation Working Group; Brors B, Rippe K, Jones DTW, Feuerbach L; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 11:733. doi: 10.1038/s41467-019-13824-9

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium [Incl Bjerkehagen B, Myklebost O, Zaikova O] (2020) Pan-cancer analysis of whole genomes. Nature 578:82–93 doi:10.1038/s41586-020-1969-6 

Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020) Mutational Dynamics and Immune Evasion in Diffuse Large B-cell Lymphoma: A Call for Relapse Sampling Blood Adv 12;4(9):1859-1866. doi: 10.1182/bloodadvances.2019001325. 

Yakneen S, Waszak SM; PCAWG Technical Working Group; Gertz M, Korbel JO; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Butler enables rapid cloud-based analysis of thousands of human genomes. Nat Biotechnol. 38:288-292. doi: 10.1038/s41587-019-0360-3

Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, Yang Y, Martincorena I, Creighton CJ, Weinstein JN, Xu Y, Han L, Kim HL, Nakagawa H, Park K, Campbell PJ, Liang H; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 52:342-352. doi: 10.1038/s41588-019-0557-x

Zhang Y, Chen F, Fonseca NA, He Y, Fujita M, Nakagawa H, Zhang Z, Brazma A; PCAWG Transcriptome Working Group; PCAWG Structural Variation Working Group; Creighton CJ; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nat Commun. 11:736. doi: 10.1038/s41467-019-13885-w

Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O (2019) Preclinical evaluation of the pan-FGFR inhibitor LY2874455 in FRS2-amplified liposarcoma. Special Issue «Fibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor: Cells 2019, 8(2), 189; PDF (Open Access) DOI:10.3390/cells8020189 

Løvf M, Zhao S, Axcrona U, Johannesen B, Bakken AC, Carm KT, Hoff AH, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI (2019) Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity. Eur Urology DOI: 10.1016/j.eururo.2018.08.009

Myklebost O (Ed) Genomsekvensering for bedre persontilpasning av kreftbehandling. (100 siders rapport fra Norsk KreftGenomikkonsortium) Jan 2019 pdf 

Nakken​ S, Saveliev​ V, Hofmann​ O, Møller​ P, Myklebost​ O, Hovig E Cancer Predisposition Sequencing Reporter (CPSR): a flexible variant report engine for germline screening in cancer (2019) bioRxiv preprint doi:10.1101/846089​

Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O,Knappskog S, Lønning PE (2018) Patterns of genomic evolution in advanced melanoma. Nature Comm DOI: 10.1038/s41467-018-05063-1  

Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E (2018) Preclinical evaluation of vemurafenib as therapy for BRAFV600E mutated sarcomas Int J Mol Sci DOI:10.3390/ijms19040969 

Kresse SK, Namløs HM, Lorenz S, Berner JM, Ola Myklebost O, Bjerkehagen B, Meza-Zepeda LA(2018) Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples. PLoS One https://doi.org/10.1371/journal.pone.0197456 

Nakken S, Fournous G, Vodak D, Aasheim B, Myklebost O, Hovig E (2017) Personal Cancer Genome Reporter: Variant Interpretation Report For Precision Oncology. Bioinformatics 1–3 doi:10.1093/bioinformatics/btx817 

Namløs H, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA(2018) Non-invasive detection of ctDNA reveals intratumour heterogeneity and is significantly associated with aggressive GIST Mol Cancer Ther DOI: 10.1158/1535-7163.MCT-18-0174

Serguienko A, Wang MY, Myklebost O(2018) Real-time vital mineralization detection and quantification during in vitro osteoblast differentiation. Biological Procedures Online (2018) 20:14 DOI: 10.1186/s12575-018-0079-4 

Strauss SJ, Anninga J, Baglio B, Baumhoer D, Behjati S, Bielack S, Boye K, Broto JM, Cleton‑Jansen AM, Degasperi A, Evans A, Fagioli F, Fiocco M, Gaspar N, Heymann D, Hindi N, Lancia C, Myklebost O, Nathrath M, Redini F, Scotlandi K, Tirtei E, Vanden Eynden M, Whelan J (2018) Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma Clin Sarcoma Res 8:17 DOI:10.1186/s13569-018-0103-0 

Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E (2018) Sample-Index Misassignment Impacts Tumour Exome Sequencing Sci. Rep. DOI:10.1038/s41598-018-23563-4 

Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I, Cooke SL, Davies H, Mifsud W, Lidgren M, Martin S, Latimer C, Maddison M, Butler AP, Teague JW, Pillay N, Shlien A, McDermott U, Futreal PA, Baumhoer D, Zaikova O, Bjerkehagen B, Myklebost O, Amary MF, Tirabosco R, Van Loo P, Stratton MR, Flanagan AM, Campbell PJ (2017) Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma Nature Communications 23:15936 doi: 10.1038/ncomms15936

Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA (2017) Multi-omics of 34 colorectal cancer cell lines – a resource for biomedical studies Mol Cancer 16:116 doi: 10.1186/s12943-017-0691-y

Engkvist ME, Stratford EW, Lorenz S, Meza-Zepeda LA, Munthe E, Myklebost O (2017) Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b Sci Rep DOI:10.1038/s41598-017-10189-1

Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2017) Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report BMC Cancer 17:29 Doi: 10.1186/s12885-016-2992-8

Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA (2017) High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival. Int J Cancer 141:184-190 doi: 10.1002/ijc.30726

Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A (2017) Monitoring of Multiple Myeloma by quantification of recurrent mutations in serum Haematologica 102:1266-1272 doi: 10.3324/haematol.2016.160564

Serguienko A, Hanes R,Grad I, Wang MY, Munthe E, Myklebost O (2017) PP2A regulatory subunit B55γ is a gatekeeper of osteoblast maturation and lineage maintenance Stem Cells Devel 26: 1375-1383 doi: 10.1089/scd.2017.0129

Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017) Multilevel genomics of colorectal cancers with microsatellite instability – clinical impact of JAK1 mutations and consensus molecular subtype 1 Genome Medicine 9:46 doi: 10.1186/s13073-017-0434-0

Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall L, Judson I, Seddon B, Cambell IG, Young MA, Sarin R, Blay JY, O’Donoghue SI, Thomas D (2016) Novel monogenic and polygenic determinants of sarcoma risk: an international study of 1162 families Lancet Oncology 17:1261–1271 PDF

• Editorial Comment: Are sarcomas hereditary? 
• Editorial comment in Cancer Discovery: Unfurling the Genetic Map of Sarcomas

Barøy T, Chilamakuri CSR, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA (2016) Genome analysis of osteosarcoma progression samples identifies FGFR1 overexpression as a potential treatment target and CHM as a candidate tumor suppressor gene Plos One 11: e0163859 DOI:10.1371/journal.pone.0163859

Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O; Børresen-Dale AL, Brustugun OT, Helland Å (2016) TP53 mutation spectrum in smokers and never smoking lung cancer patients Frontiers in Genetics 7:85.

Hanes, R., I. Grad, S. Lorenz, E. W. Stratford, E. Munthe, C. C. S. Reddy, L. A. Meza-Zepeda and O. Myklebost(2016). Amplified FRS2 identified as a target for treatment of dedifferentiated liposarcoma by genome sequencing and functional validation. Oncotarget 7:54583.

Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JV, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley MC, McCabe MG, Metzler M, Myklebost O, Nathrath M, Picci P, Potratz J, Redini F, Richter GH, Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G, Bielack SS (2016) The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. Clin Sarcoma Res. 16;6:3

Sandhu V, Wedge DC, Lothe IMB, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børressen-Dale AL, Ikdahl T, Van Loo P, Nord S (2016) The genomic landscape of pancreatic and periampullary adenocarcinoma. Cancer Research 76(17); 1–11

Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T (2016)
VOLIN and KJON-Two novel hyperdiploid myeloma cell lines Genes Chromosomes Cancer, 55 (11), 890-901
PubMed 27311012

Budin-Ljøsne I, Bentzen HB, Solbakk JH, Myklebost O (2015) Genome sequencing in research requires a new approach to consent Tidskr Nor Legeforening PDF

Chymkowitch P, Nguéa P A, Aanes H, Koehler CJ, Thiede B, Lorenz S, Meza-Zepeda LA, Klungland A, Enserink JM (2015) Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes Genome Res, 25 (6), 897-906 PubMed 25800674

Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z et al. (2015) Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biol, 16, 7 PubMed 25650807

Ju YS, Tubio JMC, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A,Gerstung M, ICGC Prostate Cancer Working Group, ICGC Bone Cancer Working Group, ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Ta M, Lee M, van’t Veer LJ, Tan BKT, Aparicio S, Span PN, Martens JWM, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PM, Stratton MR (2015) Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells Genome Res 25:814-24. doi: 10.1101/gr.190470.115

Kanojia D, Nagata Y, Garg M, Lee DH, Anand MT, Christoph H, Klein HU, Said JW, Doan NB, Mohith S, Gunasekar S, Myklebost O, Yang H, Dugas M, Meza‐Zepeda LA, Silberman AW, Forscher C, Ogawa S, Koeffler HP (2015) Genomic landscape of liposarcoma Oncotarget DOI: 10.18632/oncotarget.6464

Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GOS, Skotheim RI, Lothe RA, Tarpey P, Campbell P, Flanagan A, Meza-Zepeda LA, Myklebost O (2015) Unscrambling the genomic chaos of osteosarcoma reveals recurrent rearrangements and frequent novel TP53 aberrations Oncotarget DOI: 10.18632/oncotarget.6567

Myklebost O (2015) Personalized cancer therapy for soft tissue sarcomas: progress and pitfalls (Review) Personalized Medicine 12:593-602 PDF

Myklebost O (2015) Norwegian Cancer Genomics Consortium, a platform for research on personalized cancer medicine in a public health system. Drug Discovery Today: Special issue on Stratified Medicine doi:10.1016/j.drudis.2015.10.003

Naderi EH, Ugland H, Myklebost O, Sandnes DL, Torgersen ML, Josefsen D, Ellen Ruud E, Naderi S, Blomhoff HK (2015) Bone marrow stroma-derived PGE₂ protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death, Mol Cancer in press doi:10.1186/s12943-014-0278-9

Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost, Ola, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E,Sandvik A, Wader KF, Misund K, Sundan A, Aarset H, Waage A (2015) Clinical and biological implications of BRAF V600E mutation in multiple myeloma. Blood Cancer J doi:  10.1038/bcj.2015.24

Safavi S, Järnum S, Vannas C, Udane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Stratford EW, Myklebost O, Eriksson M, Stock ES, Ståhlberg A, Åman P (2015) HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget  PDF

Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Ola Myklebost O, Munthe E (2015) Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA Oncotarget 6(4): 2451–2465